Extinction of insulin-like growth factor-i mitogenic signaling by antiestrogen-stimulated fas-associated protein tyrosine phosphatase-1 in human breast cancer cells

Molecular Endocrinology

Volumn 12, Issue 4, 1998, Pages 568-579

  Freiss, Gilles ^a   Puech, Carole ^a   Vignon, Françoise ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; CD45 ANTIGEN; ESTROGEN RECEPTOR; FAS ANTIGEN; FULVESTRANT; HYDROXYTAMOXIFEN; PROTEIN TYROSINE PHOSPHATASE; SOMATOMEDIN C;

ARTICLE; BREAST CANCER; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG MECHANISM; ENZYME REGULATION; HORMONAL CARCINOGENESIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

EID: 0032230366     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/mend.12.4.0088     Document Type: Article

References (51)

1. The effect of estrogens and antiestrogens on hormone-responsive human breast cancer in long term tissue culture
2. Epidermal growth factor stimulation of human breast cancer cells in culture
3. Somatomedin-C receptors and growth effects in human breast cancer cells maintained in long-term tissue culture
4. Differential responsiveness of human breast cancer cell line MCF7 and T47D to growth factors and 17β- estradiol
5. Growth factors in breast cancer
6. Control of breast cancer cell growth by steroids and growth factors: Interactions and mechanisms
7. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation
8. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase
9. Coupling of dual signaling pathways: EGF action involves the estrogen receptor
10. Antiestrogens inhibit the mitogenic effect of growth factors on breast cancer cells in the total absence of estrogens
11. Antisteroidal and anti-growth factor activities of anti-estrogens
12. Physiological coupling of growth factor and steroid receptor signaling pathways: Estrogen receptor knockout mice lack estrogen-like response to epidermal growth factor
13. Endocrine effects of adjuvant chemotherapy and long-term tamoxifen administration on node-positive patients with breast cancer
14. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer
15. Effects of tamoxifen on cardiovascular risk factors in post-menopausal women after 5 years of treatment
16. Raloxifen (LY 139481) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats
17. Antiestrogens antagonize the stimulatory effect of epidermal growth factor on the induction of progesterone receptor in fetal uterine cells in culture
18. Multihormonal regulation of the progesterone receptor in MCF7 human breast cancer cells: Interrelationships among insulin, insulin-like growth factor-I, serum and estrogen
19. Estradiol increases and anti-estrogens antagonize the growth factor-induced activator protein-1 activity in MCF7 cells breast cancer cells without affecting c-fos and c-jun synthesis
20. Antiestrogens increase protein tyrosine phosphatase activity in human breast cancer cells
21. Structural diversity and evolution of human receptor-like protein tyrosine phosphatases
22. 'Zip codes' direct intracellular protein tyrosine phosphatases to the correct cellular 'address'
23. Homophilic interactions mediated by receptor tyrosine phosphatases μ and kappa A critical role for the novel extracellular MAM domain
24. Activation of transcription via AP-1 or CREB regulatory sites is blocked by protein tyrosine phosphatases
25. Expression of a transmembrane phosphotyrosine phosphatase inhibits cellular response to platelet-derived growth factor and insulin-like growth factor-1
26. Transforming growth factor-β1 inhibits human keratinocyte proliferation by upregulation of a receptor-type tyrosine phosphatase R-PTP-kappa gene expression
27. Differential activities of protein tyrosine phosphatases in intact cells
28. Protein tyrosine phosphatase activation during nerve growth factor-induced neuronal differentiation of PC12 cells
29. Receptor protein tyrosine phosphatase α activates pp60(c-src) and is involved in neuronal differentiation
30. The protein tyrosine phosphatase DEP-1 is induced during differentiation and inhibits growth of breast cancer cells
31. p80cdc25 Mitotic inducer is the tyrosine phosphatase that activates p34cdc2 kinase in fission yeast
32. Rapid activation of the T-cell tyrosine protein kinase pp561ck by the CD45 phosphotyrosine phosphatase
33. Cell transformation and activation ofpp60(c-src) by overexpression of a protein tyrosine phosphatase
34. A family of receptor-linked protein phosphatases in humans and Drosophila
35. Characterization of PCP-2, a novel receptor protein tyrosine phosphatase of the MAM family domain
36. A new member of the immunoglobulin superfamily that has a cytoplasmic region homologous to the leukocyte common antigen
37. A novel protein-tyrosine phosphatase with homology to both the cytoskeletal proteins of the band 4.1 family and junction-associated guanylate kinases
38. Cloning and characterization of PTPL1, a protein tyrosine phosphatase with similarities to cytoskeletal-associated proteins
39. FAP-1: A protein tyrosine phosphatase that associates with Fas
40. Molecular cloning of a novel protein-tyrosine phosphatase containing a membrane-binding domain and GLGF repeats
41. Insulin receptor signaling is augmented by antisense inhibition of the protein tyrosine phosphatase LAR
42. Expression of the receptor-linked protein tyrosine phosphatase LAR: Proteolytic cleavage and shedding of the CAM-like extracellular region
43. The LAR transmembrane protein tyrosine phosphatase and a coiled-coil LAR-inter-acting protein co-localize at focal adhesions
44. Identification of a hormonally regulated protein tyrosine phosphatase associated with bone and testicular differentiation
45. Phorbol ester-induced expression, phosphorylation, and translocation of protein tyrosine phosphatase 1C in HL-60 cells
46. The quinone reductase gene: A unique estrogen-receptor regulated gene that is activated by antiestrogens
47. The Fas death factor
48. Fas expression and function in normal and malignant breast cell lines
49. Tamoxifen interferes with the insulin-like growth factor I receptor (IGF-IR) signaling pathway in breast cancer cells
50. Computer-aided quantification of RNA levels detected by in situ hybridization of tissue sections
51. The fluorometric measurement of deoxyribonucleic acid in animal tissues with special reference to the central nervous system